STOCK TITAN

Orgenesis Inc - ORGS STOCK NEWS

Welcome to our dedicated news page for Orgenesis (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orgenesis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orgenesis's position in the market.

Rhea-AI Summary
Orgenesis Inc. announces continued progression of its Point of Care (POCare) network and infrastructure for advanced therapeutic services and facilities. The company's subsidiary, Octomera, has been confirmed as an industrial partner to the University of California Davis, following a recent California Institute of Regenerative Medicine (CIRM) grant. The collaboration aims to standardize Good Manufacturing Practice (GMP) manufacturing capabilities and create a network to harmonize operations for cell and gene therapy manufacturing. UC Davis and Orgenesis are interested in expanding the point of care (POC) network model to decentralize medical innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
partnership
-
Rhea-AI Summary
Orgenesis Inc. has withdrawn its proposed underwritten public offering of securities due to market conditions. The company is a global biotech company focused on cell and gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.05%
Tags
-
Rhea-AI Summary
Orgenesis Inc. has announced a public offering to raise funds for working capital and general corporate purposes. The offering consists of units, including common stock and warrants, and pre-funded units. EF Hutton is the sole book-running manager for the offering. The offering is being made under a shelf registration statement and will be filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.05%
Tags
Rhea-AI Summary
Orgenesis partners with CGT Global to expand commercialization of CGTs, expecting to partner with over 200 hospitals by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Orgenesis appoints Gerhard Bauer as VP of Global Product Implementation at Octomera, enhancing process development and facilities. Octomera's flexible facilities format cuts build time to under 6 months. Bauer's expertise critical for decentralizing access to advanced medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
partnership
Orgenesis Inc

Nasdaq:ORGS

ORGS Rankings

ORGS Stock Data

16.84M
28.14M
20.99%
6.78%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Germantown

About ORGS

orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.